The global biopharmaceutical industry is undergoing a significant transformation as manufacturers seek more flexible, efficient, and cost-effective production technologies. Among the most impactful innovations driving this evolution are single-use bioreactors (SUBs), which are rapidly replacing conventional stainless-steel systems across research, development, and commercial manufacturing facilities.

According to recent market research, the global Single-Use Bioreactors Market is projected to grow from USD 4.4 billion in 2024 to USD 9.1 billion by 2029, registering an impressive CAGR of 15.4% during the forecast period. The market’s expansion is fueled by growing biologics production, increasing adoption of biosimilars, rising investments by CDMOs and CMOs, and the industry’s focus on sustainable manufacturing solutions.

What Are Single-Use Bioreactors?

Single-use bioreactors are disposable bioprocessing systems that utilize pre-sterilized plastic bags instead of traditional stainless-steel vessels. These systems are designed for cell culture and biological production processes, offering significant advantages such as reduced contamination risks, lower operational costs, faster turnaround times, and greater manufacturing flexibility.

Unlike conventional systems that require extensive cleaning, sterilization, and validation procedures, SUBs eliminate many of these labor-intensive processes, making them highly attractive for modern biomanufacturing facilities.

Key Factors Driving Market Growth

Growing Adoption Among CDMOs and CMOs

Contract Development and Manufacturing Organizations (CDMOs) and Contract Manufacturing Organizations (CMOs) are increasingly adopting single-use technologies to meet diverse client requirements while maintaining operational flexibility. SUBs allow manufacturers to switch between products more efficiently and reduce facility downtime, improving overall productivity.

Lower Capital Investment Requirements

One of the major advantages of single-use bioreactors is the reduced need for permanent infrastructure. Traditional stainless-steel facilities require substantial investments in equipment, utilities, cleaning systems, and validation procedures. In contrast, SUBs significantly lower upfront costs, enabling companies to establish manufacturing capabilities more rapidly.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=49113750

Sustainability Benefits

Environmental sustainability has become a critical consideration for biopharmaceutical manufacturers. Single-use bioreactors reduce water consumption and energy usage by eliminating cleaning and sterilization processes. This contributes to a smaller environmental footprint and aligns with global sustainability goals.

Expansion of Biologics and Biosimilars Markets

The increasing demand for monoclonal antibodies, recombinant proteins, vaccines, cell therapies, and biosimilars continues to drive the need for flexible manufacturing solutions. Single-use bioreactors offer the scalability and efficiency required to support these rapidly growing therapeutic segments.

Large-Scale Bioreactors Lead Market Demand

Based on scale range, the market is segmented into:

• ≤10 L
• 11–100 L
• 101–500 L
• 501–1,500 L
• 
  1,500 L

Among these segments, bioreactors with capacities greater than 1,500 liters accounted for the largest market share in 2023 and are expected to maintain their dominance throughout the forecast period.

The growing commercialization of high-demand biologics and vaccines has created a need for larger production capacities. Large-scale single-use bioreactors provide manufacturers with the ability to meet global demand while retaining the flexibility associated with disposable technologies.

These systems represent a significant milestone in the industry’s transition toward agile manufacturing environments capable of responding rapidly to changing market requirements and regulatory expectations.

Mammalian Cell Culture Applications Driving Growth

Based on cell type, the market is categorized into:

• Mammalian Cells
• Bacterial Cells
• Yeast Cells
• Other Cells (Insect and Plant Cells)

The mammalian cells segment is expected to register the highest growth rate during the forecast period.

Mammalian cell cultures remain the preferred platform for producing complex biologics, including monoclonal antibodies and recombinant proteins. Single-use bioreactors have demonstrated exceptional compatibility with mammalian cell processes due to their scalability, process control capabilities, and relatively manageable engineering requirements.

Compared with bacterial and yeast cultures, mammalian cells generate lower heat loads and require less aggressive oxygen transfer systems, making them particularly well-suited for single-use technologies.

As the pipeline of biologics continues to expand globally, demand for mammalian cell-based production systems is expected to accelerate significantly.

Asia Pacific Emerges as the Fastest-Growing Regional Market

While North America and Europe currently maintain substantial market shares, the Asia Pacific region is anticipated to witness the fastest growth through 2029.

Several factors are contributing to this rapid expansion:

Rising Biosimilar Production

Countries such as China, India, South Korea, and Singapore are becoming major hubs for biosimilar development and manufacturing, creating strong demand for flexible bioprocessing technologies.

Increased Investments in Biopharmaceutical Manufacturing

Global pharmaceutical companies and regional CMOs are investing heavily in advanced manufacturing facilities across Asia Pacific to capitalize on lower production costs and expanding healthcare markets.

Growing Focus on Healthcare Innovation

Governments throughout the region are actively supporting biotechnology innovation through funding programs, infrastructure development, and favorable regulatory initiatives.

These developments are creating substantial opportunities for single-use bioreactor manufacturers seeking to expand their presence in emerging markets.

Hybrid Manufacturing Facilities: A Growing Opportunity

One of the most promising trends in the market is the adoption of hybrid facilities that combine traditional stainless-steel infrastructure with single-use systems.

This approach enables manufacturers to leverage the benefits of both technologies:

• Scalability for commercial production
• Operational flexibility
• Reduced contamination risk
• Lower cleaning and validation requirements
• Improved production efficiency

Hybrid facilities are expected to play an increasingly important role as companies seek optimized manufacturing strategies for diverse biologics portfolios.

Competitive Landscape

The single-use bioreactors market is highly competitive and characterized by continuous innovation, strategic partnerships, and product development initiatives.

Leading market participants include:

• Sartorius AG
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Avantor, Inc.
• Repligen Corporation
• Getinge AB
• Eppendorf SE
• Parker Hannifin Corporation
• Entegris
• Saint-Gobain
• Corning Incorporated
• Lonza
• TECNIC Bioprocess Equipment Manufacturing
• FUJIMORI KOGYO CO., LTD.
• Kühner AG
• OmniBRx Biotechnologies
• PBS Biotech, Inc.
• ABEC, Inc.
• Esco Lifesciences Group Ltd.

These companies continue to invest in advanced bioreactor designs, automation capabilities, digital process monitoring technologies, and scalable manufacturing solutions to address evolving industry requirements.

Future Outlook

The future of the single-use bioreactors market appears exceptionally promising. As biologics pipelines expand, personalized medicine gains traction, and biosimilar production increases worldwide, manufacturers will require more agile and cost-effective production platforms.

Single-use bioreactors offer a compelling combination of flexibility, scalability, sustainability, and economic advantages that align perfectly with the needs of modern biopharmaceutical manufacturing.

With ongoing technological advancements, expanding adoption among CDMOs and CMOs, and significant growth opportunities in emerging markets, single-use bioreactors are expected to remain at the forefront of bioprocessing innovation through 2029 and beyond.

Conclusion

The global single-use bioreactors market is entering a period of accelerated growth, driven by the industry’s pursuit of flexible manufacturing, lower operating costs, and sustainable production practices. As large-scale biologics manufacturing expands and emerging regions strengthen their biopharmaceutical capabilities, single-use technologies will play a critical role in shaping the future of drug development and commercial production.

Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=49113750